Greeting

CompleCure is a drug discovery start-up that drives innovation in cancer treatment with the vision of creating a cure for patients with advanced cancer. Our foundational technology, AMDC (Antibody Mimetic Drug Conjugate), is the result of years of research with some of the world's leading experts in advanced computational science and molecular dynamics. Through the development of this supercomputer-based technology, we aim to redefine the future of cancer treatment by delivering superior therapeutic efficacy and safety compared to conventional therapies.

 

The mission of CompleCure is to provide promising treatments for patients with refractory or advanced cancers and those who no longer respond to existing therapies. We are committed to improving each patient's quality of life (QOL) by developing proprietary technologies that effectively eliminate cancer cells and prevent recurrence. Our research and development is focused on pioneering new treatment approaches using the latest antibody mimetic technology, photoimmunotherapy, and synthetic lethal induction.

 

We are also actively pursuing partnerships to foster innovation in cancer treatment and drug discovery through collaborations with the pharmaceutical and healthcare industries, including the development of manufacturing technologies in collaboration with AGC. By collaborating with multiple partners, we aim to leverage collective expertise and technology to deliver treatments to more patients, faster.

 

At CompleCure, we are committed to patients and their families and strive to remain a pioneer in cancer treatment. Our journey has just begun. We appreciate your continued support and guidance.

​

​

Masayuki Tsuchiya 

 

CEO  

 

CompleCure Inc.